Cargando…

Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors

The immune checkpoint inhibitor (ICI) ipilimumab has revolutionized the treatment of patients with different cancer histologies, including melanoma, renal cell carcinoma, and non-small cell lung carcinoma. However, only a subset of patients shows dramatic clinical responses to treatment. Despite int...

Descripción completa

Detalles Bibliográficos
Autores principales: Mason, Nicola J., Chester, Nicholas, Xiong, Ailian, Rotolo, Antonia, Wu, Ying, Yoshimoto, Sho, Glassman, Patrick, Gulendran, Gayathri, Siegel, Don L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726733/
https://www.ncbi.nlm.nih.gov/pubmed/34856888
http://dx.doi.org/10.1080/19420862.2021.2004638
_version_ 1784626363555119104
author Mason, Nicola J.
Chester, Nicholas
Xiong, Ailian
Rotolo, Antonia
Wu, Ying
Yoshimoto, Sho
Glassman, Patrick
Gulendran, Gayathri
Siegel, Don L.
author_facet Mason, Nicola J.
Chester, Nicholas
Xiong, Ailian
Rotolo, Antonia
Wu, Ying
Yoshimoto, Sho
Glassman, Patrick
Gulendran, Gayathri
Siegel, Don L.
author_sort Mason, Nicola J.
collection PubMed
description The immune checkpoint inhibitor (ICI) ipilimumab has revolutionized the treatment of patients with different cancer histologies, including melanoma, renal cell carcinoma, and non-small cell lung carcinoma. However, only a subset of patients shows dramatic clinical responses to treatment. Despite intense biomarker discovery efforts linked to clinical trials using CTLA4 checkpoint blockade, no single prognostic correlate has emerged as a valid predictor of outcome. Client-owned, immune competent, pet dogs develop spontaneous tumors that exhibit similar features to human cancers, including shared chromosome aberrations, molecular subtypes, immune signatures, tumor heterogeneity, metastatic behavior, and response to chemotherapy. As such, they represent a valuable parallel patient population in which to investigate novel predictive biomarkers and rational therapeutic ICI combinations. However, the lack of validated, non-immunogenic, canine ICIs for preclinical use hinders this comparative approach. To address this, fully canine single-chain variable fragments (scFvs) that bind canine CTLA4 were isolated from a comprehensive canine scFv phage display library. A lead candidate for clinical development was selected based on its subnanomolar binding affinity to canine CTLA4 and its ability to prevent CTLA4 binding to CD80/CD86 and promote T cell proliferation and effector function. In vivo mouse studies revealed pharmacokinetics similar to isotype control IgG with no evidence of short-term adverse effects. This work paves the way for in vivo analysis of the first fully canine, anti-canine CTLA4 antibody to promote anti-tumor immunity in dogs with immune-responsive cancers and provide an important comparative tool to investigate correlative biomarkers of response and mechanisms of resistance to CTLA4 checkpoint inhibition.
format Online
Article
Text
id pubmed-8726733
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-87267332022-01-05 Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors Mason, Nicola J. Chester, Nicholas Xiong, Ailian Rotolo, Antonia Wu, Ying Yoshimoto, Sho Glassman, Patrick Gulendran, Gayathri Siegel, Don L. MAbs Report The immune checkpoint inhibitor (ICI) ipilimumab has revolutionized the treatment of patients with different cancer histologies, including melanoma, renal cell carcinoma, and non-small cell lung carcinoma. However, only a subset of patients shows dramatic clinical responses to treatment. Despite intense biomarker discovery efforts linked to clinical trials using CTLA4 checkpoint blockade, no single prognostic correlate has emerged as a valid predictor of outcome. Client-owned, immune competent, pet dogs develop spontaneous tumors that exhibit similar features to human cancers, including shared chromosome aberrations, molecular subtypes, immune signatures, tumor heterogeneity, metastatic behavior, and response to chemotherapy. As such, they represent a valuable parallel patient population in which to investigate novel predictive biomarkers and rational therapeutic ICI combinations. However, the lack of validated, non-immunogenic, canine ICIs for preclinical use hinders this comparative approach. To address this, fully canine single-chain variable fragments (scFvs) that bind canine CTLA4 were isolated from a comprehensive canine scFv phage display library. A lead candidate for clinical development was selected based on its subnanomolar binding affinity to canine CTLA4 and its ability to prevent CTLA4 binding to CD80/CD86 and promote T cell proliferation and effector function. In vivo mouse studies revealed pharmacokinetics similar to isotype control IgG with no evidence of short-term adverse effects. This work paves the way for in vivo analysis of the first fully canine, anti-canine CTLA4 antibody to promote anti-tumor immunity in dogs with immune-responsive cancers and provide an important comparative tool to investigate correlative biomarkers of response and mechanisms of resistance to CTLA4 checkpoint inhibition. Taylor & Francis 2021-12-02 /pmc/articles/PMC8726733/ /pubmed/34856888 http://dx.doi.org/10.1080/19420862.2021.2004638 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Report
Mason, Nicola J.
Chester, Nicholas
Xiong, Ailian
Rotolo, Antonia
Wu, Ying
Yoshimoto, Sho
Glassman, Patrick
Gulendran, Gayathri
Siegel, Don L.
Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
title Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
title_full Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
title_fullStr Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
title_full_unstemmed Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
title_short Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
title_sort development of a fully canine anti-canine ctla4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726733/
https://www.ncbi.nlm.nih.gov/pubmed/34856888
http://dx.doi.org/10.1080/19420862.2021.2004638
work_keys_str_mv AT masonnicolaj developmentofafullycanineanticaninectla4monoclonalantibodyforcomparativetranslationalresearchindogswithspontaneoustumors
AT chesternicholas developmentofafullycanineanticaninectla4monoclonalantibodyforcomparativetranslationalresearchindogswithspontaneoustumors
AT xiongailian developmentofafullycanineanticaninectla4monoclonalantibodyforcomparativetranslationalresearchindogswithspontaneoustumors
AT rotoloantonia developmentofafullycanineanticaninectla4monoclonalantibodyforcomparativetranslationalresearchindogswithspontaneoustumors
AT wuying developmentofafullycanineanticaninectla4monoclonalantibodyforcomparativetranslationalresearchindogswithspontaneoustumors
AT yoshimotosho developmentofafullycanineanticaninectla4monoclonalantibodyforcomparativetranslationalresearchindogswithspontaneoustumors
AT glassmanpatrick developmentofafullycanineanticaninectla4monoclonalantibodyforcomparativetranslationalresearchindogswithspontaneoustumors
AT gulendrangayathri developmentofafullycanineanticaninectla4monoclonalantibodyforcomparativetranslationalresearchindogswithspontaneoustumors
AT siegeldonl developmentofafullycanineanticaninectla4monoclonalantibodyforcomparativetranslationalresearchindogswithspontaneoustumors